Clinical trial · Observational
Adaptive Radiotherapy for High-risk Prostate Cancer Using Multiparametric MRI
Adaptive Radiotherapy for High-risk Prostate Cancer Using Multiparametric MRI (ARPC-MRI) - a Feasibility Study
NCT03967080CI-TRIAL-00094450ARPC-MRIcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This small study will investigate the feasibility of using multi-parametric MRI to introduce and support adaptive radiotherapy treatments for high-risk prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (6)
- measure
- Reproducability of DW-MRI
- timeFrame
- 7 months
- description
- Apparent diffusion coefficient (ADC)
- measure
- Reproducibility of DCE-MRI
- timeFrame
- 7 months
- description
- Using volume transfer constant
- measure
- Reproducibility of DCE-MRI
- timeFrame
- 7 months
- description
- Using leakage space as a percentage of unit volume
- measure
- Reproducibility of DCE-MRI
- timeFrame
- 7 months
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. New diagnosis of high-risk prostate cancer: any of: 1. Gleason score of 8, 9 or 10 2. PSA \> 20 3. T3/4 2. Patient due to receive androgen deprivation therapy (ADT) 3. Prescribed 78Gy/39# external beam radiotherapy 4. Measurable dominant intraprostatic tumour on diagnostic imaging of at least 10mm diameter 5. ≥18 years of age 6. ECOG performance status of 0-1 7. Informed, written and witnessed consent to participate is required. Exclusion Criteria: 1. Patients who are not due to receive androgen deprivation therapy (ADT) 2. Any contraindication to MRI scanning including contraindication to MRI contrast agents 3. Previous radiotherapy to the pelvis 4. Any physical or social reasons that would make attendance for additional visits impossible. 5. Any patient with or planned for prostate fiducial markers. 6. Unable to give informed consent. 7. Patients currently enrolled in an interventional clinical trial.
References
Publications (0)
Data not yet available
No reference posted for this study.